JW Therapeutics Initiates Clinical Study of JWATM214 for the Treatment of Advanced Hepatocellular Carcinoma
- The company initiates the first-in-human clinical study of JWATM214 for advanced HCC. The study focuses to evaluate the safety & tolerability, determine the RP2D & assess the PK profile & preliminary efficacy of JWATM214 for GPC-3-expressing advanced HCC
- JWATM214 is an autologous T-cell immunotherapy candidate drug targeting GPC-3 that has been developed using Eureka's ARTEMIS technology & Lyell's T-cell anti-exhaustion technology
- In 2020, JW Therapeutics collaborated with Eureka & Lyell and in-licensed the rights to Eureka's ARTEMIS technology & Lyell's T cell anti-exhaustion technology to develop, manufacture & commercialize products in China (incl. mainland China, Hong Kong, Macao & Taiwan) along with ASEAN member states
Ref: PRNewswire | Image: JW Therapeutics
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.